Split up the chairman/CEO role at Allergan — activist investor; Zogenix files for FDA, EMA approval of seizure drug
→ Citing Allergan’s “chronic underperformance” under Brett Saunders — the current board chairman and CEO — investor David Tepper
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
